Document Detail

Tranexamic acid-bevacizumab synergy in HHT patients presenting pulmonary arteriovenous malformations.
MedLine Citation:
PMID:  22959314     Owner:  NLM     Status:  MEDLINE    
Bevacizumab and tranexamic acid have shown efficacy in the treatment of epistaxis and liver involvement of HHT patients. We suggest therapeutic association of bevacizumab and tranexamic acid should be further evaluated for the prevention and treatment of early lung involvement in HHT.
Alexis Lacout; Pierre Yves Marcy; Mostafa El Hajjam; Pascal Lacombe
Related Documents :
17473244 - Bacillus decisifrondis sp. nov., isolated from soil underlying decaying leaf foliage.
18044924 - Total syntheses of (-)-alpha-kainic acid and (+)-alpha-allokainic acid via stereoselect...
8478334 - Alpha-keto acids are novel siderophores in the genera proteus, providencia, and morgane...
11482734 - Initial catabolic steps of isoleucine, the r-pathway and the origin of alloisoleucine.
320184 - Control of cell division in escherichia coli: effect of amino acid starvation.
22180354 - Atorvastatin and fenofibric acid differentially affect the release of adipokines in the...
Publication Detail:
Type:  Journal Article     Date:  2012-09-05
Journal Detail:
Title:  Medical hypotheses     Volume:  79     ISSN:  1532-2777     ISO Abbreviation:  Med. Hypotheses     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-10-12     Completed Date:  2013-03-17     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  7505668     Medline TA:  Med Hypotheses     Country:  United States    
Other Details:
Languages:  eng     Pagination:  605-6     Citation Subset:  IM    
Copyright Information:
Copyright © 2012 Elsevier Ltd. All rights reserved.
Centre d'imagerie Médicale, 47, Boulevard du Pont Rouge, 15000 Aurillac, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Monoclonal, Humanized / therapeutic use*
Arteriovenous Malformations / complications*
Drug Synergism
Telangiectasia, Hereditary Hemorrhagic / complications,  drug therapy*
Tranexamic Acid / therapeutic use*
Reg. No./Substance:
0/Antibodies, Monoclonal, Humanized; 1197-18-8/Tranexamic Acid; 2S9ZZM9Q9V/bevacizumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Zinc and multi-mineral supplementation should mitigate the pathogenic impact of cadmium exposure.
Next Document:  Growth, tolerance efficiency and phytoremediation potential of Ricinus communis (L.) and Brassica ju...